ROLE OF CONCENTRATION-DEPENDENT PLASMA-PROTEIN BINDING IN DISOPYRAMIDE DISPOSITION

被引:167
作者
MEFFIN, PJ [1 ]
ROBERT, EW [1 ]
WINKLE, RA [1 ]
HARAPAT, S [1 ]
PETERS, FA [1 ]
HARRISON, DC [1 ]
机构
[1] STANFORD UNIV,SCH MED,DIV CARDIOL,PHARMACOKINET LAB,STANFORD,CA 94305
来源
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS | 1979年 / 7卷 / 01期
关键词
disopyramide; nonlinear disposition; plasma protein binding;
D O I
10.1007/BF01059439
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Plasma disopyramide concentration-time data and plasma protein binding measurements were obtained in 12 patients requiring disopyramide for suppression of their cardiac arrhythmias. The fraction of disopyramide unbound to plasma proteins varies from approximately 0.19 to 0.46 over the therapeutic range of total plasma concentrations (2-8 mg/liter). Data from single and multiple intravenous doses were analyzed using two models based on the hypothesis either that clearance is independent of the total disopyramide plasma concentration (total clearance model) or that clearance is independent of the concentration of disopyramide unbound to plasma proteins (free clearance model). This analysis indicates that only the free clearance model satisfactorily describes the data as a linear system. Using the free clearance model and data obtained from single doses, multiple intravenous infusions were designed for each patient which would rapidly attain and maintain predetermined plasma disopyramide concentrations. The calculated and observed disopyramide concentrations were in close agreement. In the 12 patients studied, at any given total disopyramide plasma concentration, there was an approximately twofold range in the fraction of disopyramide unbound to plasma proteins. Mean plasma protein binding data are therefore of little value in a given patient for predicting free disopyramide concentrations from measurements of total disopyramide concentration. Difficulties in the clinical management of patients receiving disopyramide, resulting from the nonlinear disposition of the usually measured total disopyramide concentrations, are discussed. © 1979 Plenum Publishing Corporation.
引用
收藏
页码:29 / 46
页数:18
相关论文
共 18 条
  • [1] STATISTICAL ESTIMATIONS IN PHARMACOKINETICS
    BOXENBAU.HG
    RIEGELMA.S
    ELASHOFF, RM
    [J]. JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1974, 2 (02): : 123 - 148
  • [2] OBSERVATIONS ON THE ANTIRHEUMATIC AND PHYSIOLOGIC EFFECTS OF PHENYLBUTAZONE (BUTAZOLIDIN) AND SOME COMPARISONS WITH CORTISONE
    BRODIE, BB
    LOWMAN, EW
    BURNS, JJ
    LEE, PR
    CHENKIN, T
    GOLDMAN, A
    WEINER, M
    STEELE, JM
    [J]. AMERICAN JOURNAL OF MEDICINE, 1954, 16 (02) : 181 - 190
  • [3] EFFECTS OF URINE PH AND PLASMA-PROTEIN BINDING ON RENAL CLEARANCE OF DISOPYRAMIDE
    CUNNINGHAM, JL
    SHEN, DD
    SHUDO, I
    AZARNOFF, DL
    [J]. CLINICAL PHARMACOKINETICS, 1977, 2 (05) : 373 - 383
  • [4] DEGRAEVE J, 1977, THERAPIE, V32, P195
  • [5] CLINICAL PHARMACOKINETICS OF ANTIARRHYTHMIC DRUGS
    HARRISON, DC
    MEFFIN, PJ
    WINKLE, RA
    [J]. PROGRESS IN CARDIOVASCULAR DISEASES, 1977, 20 (03) : 217 - 242
  • [6] PHARMACOKINETICS OF ANTIARRHYTHMIC DISOPYRAMIDE IN HEALTHY HUMANS
    HINDERLING, PH
    GARRETT, ER
    [J]. JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1976, 4 (03): : 199 - 230
  • [7] HULTING J, 1976, J INT MED RES, V4, P90
  • [8] KARIM A, 1975, ANGIOLOGY, V26, P85
  • [9] KNOTT S, 1971, MODEL LAB USERS DOCU
  • [10] DRUG-THERAPY - BINDING OF DRUGS TO SERUM-ALBUMIN .1.
    KOCHWESER, J
    SELLERS, EM
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1976, 294 (06) : 311 - 316